Centessa Pharmaceuticals

Janpix Ltd. is a biopharmaceutical company focused on developing targeted cancer therapies through the inhibition of Signal Transducer and Activator of Transcription (STAT) proteins. Founded in 2017 and headquartered in Cambridge, Massachusetts, with a research facility in Mississauga, Canada, Janpix specializes in the discovery of inhibitors for multiple STAT proteins, including STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, and STAT3/5. The company is particularly noted for its research on the role of certain STAT proteins, especially STAT3 and STAT5, in cancer, specifically in hematological tumors and glioblastomas. Janpix has developed novel chemistry solutions to effectively target and inhibit the function of these proteins, aiming to modulate immune responses and improve the tumor microenvironment to facilitate cancer eradication and provide patients with better therapeutic options.